BioLine RX Ltd Cash Flow Conversion Efficiency

Latest as of June 2026: -0.193x

BioLine RX Ltd cash flow conversion efficiency. Based on the latest financial reports, BioLine RX Ltd (BLRX) has a cash flow conversion efficiency ratio of -0.193x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-3.19 Million ≈ $-8.56K USD) by net assets (ILA16.51 Million ≈ $44.26K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of BioLine RX Ltd (2010–2025)

Cash flow conversion efficiency of BioLine RX Ltd from 2010 to 2025. This chart illustrates how BioLine RX Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BioLine RX Ltd (BLRX) share price today for real-time trading data and today's change.

BioLine RX Ltd Cash Flow Conversion Ratio Explained

BioLine RX Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

BioLine RX Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BioLine RX Ltd ranked by their cash flow conversion efficiency. Also see BLRX company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
PowerBank Corporation NEO:PBK	0.079x
Holista Colltech Ltd AU:HCT	-0.382x
Comperia.pl S.A. WAR:CPL	0.078x
Alkali Metals Limited NSE:ALKALI	0.040x
AlphaTON Capital Corp. NASDAQ:ATON	-0.080x
JE Cleantech Holdings Ltd NASDAQ:JCSE	0.001x
Vantage Corp NYSE MKT:VNTG	0.077x
Aakash Exploration Services Limited NSE:AAKASH	0.010x

Annual Cash Flow Conversion Efficiency for BioLine RX Ltd (2010–2025)

The table below shows the annual cash flow conversion efficiency of BioLine RX Ltd from 2010 to 2025. Review free cash flow generation of BioLine RX Ltd to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	ILA23.35 Million ≈ $62.60K	ILA-8.74 Million ≈ $-23.43K	-0.374x	+88.52%
2024-12-31	ILA13.46 Million ≈ $36.09K	ILA-43.87 Million ≈ $-117.62K	-3.259x	-90.63%
2023-12-31	ILA13.22 Million ≈ $35.45K	ILA-22.61 Million ≈ $-60.61K	-1.710x	-231.27%
2022-12-31	ILA50.84 Million ≈ $136.30K	ILA-26.24 Million ≈ $-70.35K	-0.516x	-49.07%
2021-12-31	ILA68.09 Million ≈ $182.54K	ILA-23.57 Million ≈ $-63.20K	-0.346x	+67.13%
2020-12-31	ILA22.03 Million ≈ $59.06K	ILA-23.21 Million ≈ $-62.21K	-1.053x	-55.13%
2019-12-31	ILA33.38 Million ≈ $89.49K	ILA-22.67 Million ≈ $-60.77K	-0.679x	-15.98%
2018-12-31	ILA41.32 Million ≈ $110.78K	ILA-24.19 Million ≈ $-64.86K	-0.585x	-50.68%
2017-12-31	ILA52.88 Million ≈ $141.77K	ILA-20.55 Million ≈ $-55.09K	-0.389x	+6.22%
2016-12-31	ILA35.03 Million ≈ $93.91K	ILA-14.51 Million ≈ $-38.91K	-0.414x	-39.23%
2015-12-31	ILA47.61 Million ≈ $127.64K	ILA-14.17 Million ≈ $-37.98K	-0.298x	+34.72%
2014-12-31	ILA31.77 Million ≈ $85.16K	ILA-14.48 Million ≈ $-38.82K	-0.456x	+73.68%
2013-12-31	ILA11.68 Million ≈ $31.32K	ILA-20.23 Million ≈ $-54.25K	-1.732x	-28.90%
2012-12-31	ILA14.97 Million ≈ $40.14K	ILA-20.11 Million ≈ $-53.93K	-1.344x	-169.77%
2011-12-31	ILA22.53 Million ≈ $60.41K	ILA-11.22 Million ≈ $-30.09K	-0.498x	-673.33%
2010-12-31	ILA131.96 Million ≈ $353.78K	ILA11.46 Million ≈ $30.73K	0.087x	--

About BioLine RX Ltd

TA:BLRX Israel Biotechnology

Market Cap

$8.58 Million

ILA3.20 Billion ILA

Market Cap Rank

#27342 Global

#386 in Israel

Share Price

ILA1.10

Change (1 day)

+0.00%

52-Week Range

ILA1.00 - ILA2.10

All Time High

ILA618.30